HPLC method for the determination of the S- and R-diastereomers of telaprevir for treatment of patients with hepatitis C
Keyword(s):
AbstractTelaprevir (TVR) was approved by the FDA in May 2011 for the treatment of hepatitis C. This protease inhibitor converts into two diastereomers with significant difference in antiviral activity. Clinical efficacy has been correlated with serum concentrations. Therefore, a sensitive and selective high-performance liquid chromatographic method for the simultaneous determination of both clinically relevant diastereomers of TVR was developed. Linearity ranged from 20 to 10,000 ng/mL. The coefficients of variation were <7.3%, and accuracy was between −4.0 and 5.4%. In 105 clinical samples, both diastereomers of TVR had a high degree of correlation to each other, but concentrations showed a broad range and an increase during therapy.
1977 ◽
Vol 60
(1)
◽
pp. 89-95
◽
1982 ◽
Vol 19
(1)
◽
pp. 52-56
◽
2008 ◽
Vol 91
(4)
◽
pp. 739-743
◽
2018 ◽
Vol 11
(11)
◽
pp. 118